Advaxis is pleased to be associated with
GOG in the development of this agent.
BD
Diagnostics - TriPath
In December 2006, BD (Becton,
Dickinson and Company) acquired TriPath Imaging, Inc., a maker
of innovative solutions to
improve the clinical management of cancer. This strategic acquisition aligns
innovative new technologies
with BD’s existing business strategies and is a natural complement to
ongoing internal research
programs in its BD Diagnostics and BD Biosciences segments.
These oncology management
tools are intended to span cancer screening, diagnosis, prognosis and
therapy monitoring, especially
for cancers affecting women’s health, including breast, cervical and
ovarian. This acquisition also
demonstrates BD’s commitment to bringing new technologies and
innovation to difficult
problems in healthcare, which is in line with the Company’s purpose of “Helping
all people live healthy
lives.”
About BD
BD, a leading global medical
technology company that manufactures and sells medical devices,
instrument systems and
reagents, is dedicated to improving people’s health throughout the world.
BD is focused on improving
drug therapy, enhancing the quality and speed of diagnosing infectious
diseases, and advancing
research and discovery of new drugs and vaccines. The Company’s capabilities
are instrumental in combating
many of the world’s most pressing diseases. Founded in 1897 and
headquartered in Franklin
Lakes, New Jersey, BD employs approximately 27,000 people in approximately
50 countries throughout the
world. The Company serves healthcare institutions, life science researchers,
clinical laboratories,
industry and the general public. For more information, please visit
http://www.bd.com
Biogen Idec creates new standards of care in
therapeutic areas with high unmet medical needs. Founded in
1978, Biogen Idec is a global leader in the discovery,
development, manufacturing, and commercialization of innovative
therapies. Patients in more than 90 countries benefit from
Biogen Idec's significant products that address diseases such as
lymphoma, multiple sclerosis, and rheumatoid arthritis. For
product labeling, press releases and additional information
about the company, please visit our website.
http://www.biogenidec.com
Bristol-Myers Squibb is the world leader in providing life-saving
and life-extending therapies for people with cancer. All of the
company's considerable resources and expertise in oncology are
marshaled toward the single goal of providing safer and more
effective anticancer medicines. The mission of Bristol-Myers
Squibb Oncology is to extend and enhance the lives of people
living with cancer.
http://www.BMS.com
CTI is committed to developing, acquiring, and commercializing innovative
treatments for cancer. In its pursuit of making cancer more treatable, the
Company is developing a diversified portfolio of oncology drugs. Our research
and in-licensing activities are concentrated on identifying new, less toxic,
and more effective ways to treat cancer.
CTI's product pipeline includes one marketed drug, TRISENOX, and several investigational
drugs that may address the therapeutic limitations of conventional cancer therapies.
Our most advanced investigational drug, XYOTAX (polyglutamate paclitaxel), is currently
in Phase III for non-small-cell lung and ovarian cancers. Together, these drug candidates
represent our progress in making cancer a more treatable disease.
http://www.cticseattle.com
Geisinger Health System's Department of Obstetrics and
Gynecology is seeking a BC/BE Gynecologic Oncologist.
About this position:
- Join our team of 58 women's health providers
- This position will work with Eric Bieber, MD, Chief of Women's
Services, and collaborate with Mohammed Mohiuddin, MD, FRCR,
FACR, Medical Director of The Henry Cancer Center, a
Geisinger/Fox Chase partnership.
- Our program is fully-accredited by the ACS, affiliated will
NCCTG (Mayo Clinic), ECOG, RTOB and NSABP, and interacts closely
with our Medical Oncology departments.
- This academic/clinical position joins 2 other Gynecologic
Oncologists and a Nurse Specialist on our faculty overseeing
resident and medical student education.
Geisinger Medical Center:
- Houses 75 medical and surgical specialties.
- Is a 457-bed Regional Resource Trauma Center (Level 1) with
additional qualification in pediatrics.
- Offers Life Flight® emergency aeromedical service; bringing
advanced life support to trauma sites, and transporting more
than 2,000 patients each year.
- Offers twenty-four accredited residency and fellowship
programs reflecting the system's commitment to education and
clinical excellence.
- Is conveniently located in the scenic Susquehanna Valley, less
than three hours drive from New York City, Philadelphia, and
Washington, DC.
- Offers physicians a chance to practice leading-edge medicine
while enjoying the benefits of life in small town America; good
schools, safe neighborhoods, and a wealth of cultural and
recreational activities.
Benefits:
Geisinger Health System offers its physicians the opportunity
for both professional and personal growth. We provide a
competitive income and comprehensive benefits package,
including medical malpractice coverage, four weeks vacation
and three weeks CME annually, and a generous 401K. Other
benefits of a career at Geisinger include:
- Opportunities to teach in 24 accredited residency and
fellowship programs.
- Opportunities to conduct research including clinical trials,
best practice and medical outcomes.
- Access to comprehensive health sciences libraries on both
hospital campuses, and online access to many journals and other
resources.
- Support for the pursuit of advanced degrees.
- Opportunities to practice medicine without office management
responsibilities.
- Access to advanced information technology, including online
imaging and a complete electronic medical records system.
Geisinger Health System includes:
- Geisinger Medical Center, Danville, PA, is a Regional Resource
Trauma Center (Level 1) with additional qualification in
pediatrics. A major teaching institution, Geisinger Medical
Center offers 24 accredited residency and fellowship programs.
- The Janet Weis Children's Hospital & Women's Pavilion,
Danville, PA, is the region's only tertiary care pediatric
hospital and dedicated women's health facility.
- Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA, is
a community hospital with acute care services, including The
Heart Hospital and Frank M. and Dorothea Henry Cancer Center (a
joint program of Geisinger and Fox Chase Cancer Center).
- The Sigfried and Janet Weis Center for Research, Danville, PA,
investigates a wide range of subjects with a focus on molecular
and cellular mechanisms.
- 41 single and multi-specialty physician offices throughout
Northeastern and Central Pennsylvania.
http://www.geisinger.org
Genentech is a leading biotechnology company that
discovers, develops, manufactures and commercializes biotherapeutics for
significant
unmet medical needs. Genentech manufactures and commercializes several major
oncology drugs include Herceptin, Rituxan, Avastin and Tarceva.
http://www.genentech.com
Genzyme
Biosurgery is the leader for adhesion prevention following
abdominopelvic surgery. Seprafilm®Adhesion Barrier
is a bioresorbable, site-specific barrier that separates
adhesiogenic tissue surfaces during the critical 7-day period of
peritoneal healing. In a pivotal abdominal clinical study,
Seprafilm® Adhesion Barrier patients were 8.5 times
more likely to be free of adhesions compared to control patients
(Becker 1996). No statistically significant differences were
observed in the incidence of adverse events comparing Seprafilm®
and control patients. Sepramesh®IP Bioresorbable
Coating/Permanent Mesh is indicated for the reconstruction of
soft tissue deficiencies, such as for the repair of hernias. It
is a polypropylene mesh co-knitted with polyglycolide (PGA)
fibers, which is coated on one side with a bioresorbable HA/CMC
hydrogel that minimizes unwanted adhesions between the mesh and
underlying viscera.
http://www.genzyme.com
GPC Biotech AG is a publicly
traded biopharmaceutical company focused on discovering,
developing and commercializing new anticancer drugs. GPC Biotech
has ongoing various drug development and discovery programs. GPC
Biotech AG is headquartered in Martinsried/Munich (Germany) and
has a U.S. subsidiary headquartered in Princeton, New Jersey.
http://www.gpc-biotech.com
GlaxoSmithKline
is a world leading research based pharmaceutical company with a
powerful combination of skills and resources that provides a
platform for delivery of strong growth in today’s rapidly
changing environment. GlaxoSmithKline’s mission is to improve
the quality of human life by enabling people to do more, feel
better and live longer.
GlaxoSmithKline
also has leadership in four major therapeutic areas – anti-infectives,
central nervous system, respiratory and
gastro-intestinal/metabolic. In addition, GlaxoSmithKline is a
leader in the important area of vaccines and has a growing
portfolio of oncology products, including Hycamtin (topotecan
HCL) for relapsed ovarian cancer and Navelbine (vinorelbine
tartrate). GlaxoSmithKline Oncology also has a dedicated sales
force committed to women’s cancers, including oncology medical
scientists and oncology nurse educators.
http://www.glaxosmithkline.com
ImClone Systems Incorporated is a fully integrated
global biopharmaceutical company committed to advancing
oncology care by developing and commercializing a
portfolio of targeted biologic treatments designed to
address the medical needs of patients with a variety of
cancers.
Eli Lilly and Company is a leading innovation-driven
corporation and is developing a growing portfolio of best-in-class
pharmaceutical products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Indiana, Lilly provides
answers – through medicines and information – for some of the world’s most
urgent medical needs.
Lilly Oncology is committed to providing comprehensive healthcare
solutions – answers that matter – for oncologists and cancer patients around
the world through the discovery and development of breakthrough cancer medicines.
http://www.lilly.com
.jpg)
Marshall Edwards, Inc. is a specialist oncology company
focused on the clinical development of novel anti-cancer
therapeutics. These derive from a flavonoid technology platform
which has generated a number of novel compounds characterized by
broad ranging efficacy against a range of cancer targets with
few side effects. The unique combination of efficacy and safety
has been explained by their ability to target an enzyme present
on the surface of cancer cells, thereby inhibiting the
production of pro-survival proteins within the cell. Marshall
Edwards, Inc. has licensed rights from Novogen Limited: to bring
three oncology drugs - phenoxodiol, NV-196 and NV-143 - to
market globally. Marshall Edwards, Inc. is majority owned by
Novogen, an Australian biotechnology company that is
specializing in the development of therapeutics based on a
flavonoid technology platform. Novogen, based in Sydney,
Australia, is developing a range of therapeutics across the
fields of oncology, cardiovascular disease and inflammatory
diseases. More information on phenoxodiol and on the Novogen
group of companies can be found at
www.marshalledwardsinc.com
and
www.novogen.com.
www.marshalledwardsinc.com
The mission of Merck is to provide society with
superior products and services by developing innovations and
solutions that improve the quality of life and satisfy customer
needs, and to provide employees with meaningful work and
advancement opportunities, and investors with a superior rate of
return.
Merck & Co., Inc.
is a global research-driven pharmaceutical company dedicated to
putting patients first. Established in 1891, Merck discovers,
develops, manufactures and markets vaccines and medicines to
address unmet medical needs. The company also devotes extensive
efforts to increase access to medicines through far-reaching
programs that not only donate Merck medicines but help deliver
them to the people who need them. Merck also publishes unbiased
health information as a not-for-profit service. For more
information, visit
www.merck.com.
www.merck.com
MGI PHARMA, INC. is an oncology-focused pharmaceutical company that acquires, develops and
commercializes proprietary products that address unmet cancer patient needs. MGI
PHARMA, INC. is building a balanced product portfolio of proprietary pharmaceuticals,
and intends to become a leader in oncology.
The company focuses its sales efforts solely in the United States and collaborates
with other pharmaceutical or biotechnology companies for its products in
international markets.
http://www.mgipharma.com
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of innovative
oncology products to impact the lives of people with cancer.
We are currently focusing our development efforts on
picoplatin, a new generation platinum chemotherapy agent with
the potential to become a platform product addressing multiple
indications, combinations and formulations. Picoplatin has an
improved safety profile compared to existing platinum-based
chemotherapeutics. It was designed to overcome platinum
resistance associated with chemotherapy in solid tumors and
delay time to relapse. We are studying picoplatin in multiple
cancer indications, combinations and formulations.
Our business strategy is to form partnerships to support and
expand our clinical programs and commercial opportunities and to
build a diverse portfolio of oncology product candidates. As
part of this strategy, we are collaborating with The Scripps
Research Institute on the discovery of novel, small-molecule,
multi-targeted protein kinase inhibitors as therapeutic agents
to treat cancer.
Poniard is headquartered in South San Francisco. We are
traded on the NASDAQ Global Market under the symbol PARD.
Our efforts in oncology include chemotherapy agents for acute
myeloid leukemia and a platelet growth promoter to help patients
after chemotherapy. Wyeth currently has several promising
oncology therapies in clinical trials, including treatments for
renal cell carcinoma, breast cancer, and mantle cell lymphoma.
